Tonix Pharmaceuticals and U.S. Department of Defense Military Developer in Partnership to Expand Efforts to Examine TNX-102 SL for Post-Traumatic Stress Disorder

Tonix Pharmaceuticals Holding Corp. TNXP ("Tonix"), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) to explore expansion and potential development of Tonix's investigational new drug, TNX-102 SL (cyclobenzaprine HCl sublingual tablets), for the treatment of military-related PTSD. USAMMDA is the Department of Defense's (DoD) advanced development activity for products designed to protect and preserve the lives of Warfighters. USAMMDA develops new drugs, vaccines and medical support equipment that enhance readiness, and ensures the provision of the highest quality medical care to the DoD. TNX-102 SL is a small, rapidly dissolving tablet containing very low dose cyclobenzaprine in a eutectic formulation for sublingual (under the tongue) administration and rapid absorption into the blood stream. It is designed for use at bedtime to improve sleep quality and to have a tolerability profile that supports chronic treatment.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsContracts
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!